Palatin Technologies, Inc. (PTN): Price and Financial Metrics
GET POWR RATINGS... FREE!
PTN POWR Grades
- Sentiment is the dimension where PTN ranks best; there it ranks ahead of 94.21% of US stocks.
- PTN's strongest trending metric is Momentum; it's been moving down over the last 115 days.
- PTN ranks lowest in Momentum; there it ranks in the 5th percentile.
PTN Stock Summary
- Palatin Technologies Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.13% of US listed stocks.
- For PTN, its debt to operating expenses ratio is greater than that reported by just 8.77% of US equities we're observing.
- Revenue growth over the past 12 months for Palatin Technologies Inc comes in at -100.6%, a number that bests merely 0.58% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Palatin Technologies Inc, a group of peers worth examining would be RMED, GTYH, VYGR, NPTN, and CSLT.
- Visit PTN's SEC page to see the company's official filings. To visit the company's web site, go to www.palatin.com.
PTN Stock Price Chart Interactive Chart >
PTN Price/Volume Stats
|Current price||$0.56||52-week high||$1.30|
|Prev. close||$0.55||52-week low||$0.38|
|Day high||$0.57||Avg. volume||4,101,791|
|50-day MA||$0.57||Dividend yield||N/A|
|200-day MA||$0.62||Market Cap||129.91M|
Palatin Technologies, Inc. (PTN) Company Bio
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor (MCr) 1 agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis and COVID-19. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was founded in 1986 and is based in Cranbury, New Jersey.
PTN Latest News Stream
|Loading, please wait...|
PTN Latest Social Stream
View Full PTN Social Stream
Latest PTN News From Around the Web
Below are the latest news stories about Palatin Technologies Inc that investors may wish to consider to help them evaluate PTN as an investment opportunity.
Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) announced that its 2021 Annual Meeting of Stockholders that convened on June 8, 2021, has been adjourned until July 8, 2021 at 9:00 a.m. Eastern Daylight Time to solicit additional proxies for Proposal 3, approval of an amendment to our Certificate of Incorporation to effect an increase in authorized common stock from 300,000,000 shares to 400,000,000 shares. The adjourned meeting will be a completely "virtual" meeting of stockholders,
During Q3, Palatin Technologies (AMEX: PTN ) brought in sales totaling $88.74 thousand. However, earnings decreased 29.88%, resulting in a loss of $6.49 million. In Q2, Palatin Technologies brought in $-163.97 thousand in sales but lost $9.25 million in earnings. Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative … Full story available on Benzinga.com
Palatin Hosting Key Opinion Leader Webinar in Role of Melanocortin Agonists in Inflammation and the Treatment of Ocular Indications
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that it will host a key opinion leader (KOL) webinar on melanocortin agonists for treating ocular indications, with a primary focus on PL9643, the Company's lead asset. A Phase 3 clinical study of PL9643 in patients with dry eye disease (DED) is planned for the second half of calendar year 2021. The webinar will take place on Friday, May 21, 2021 at 10:00 am Eastern Time.
Palatin to Report Third Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on May 17, 2021
Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2021 operating results on Monday, May 17, 2021 before the open of the U.S. financial markets.
Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that the United States Patent and Trademark Office (USPTO) issued Notices of Final Determination and Requirement for Election on a patent term extension for two U.S. patents covering the Vyleesi® (bremelanotide injection) drug substance, U.S. patents 6,579,968 and 6,794,489. The term of only one patent may be extended and will have an expiration date of June 25, 2025.
PTN Price Returns
Continue Researching PTNWant to see what other sources are saying about Palatin Technologies Inc's financials and stock price? Try the links below:
Palatin Technologies Inc (PTN) Stock Price | Nasdaq
Palatin Technologies Inc (PTN) Stock Quote, History and News - Yahoo Finance
Palatin Technologies Inc (PTN) Stock Price and Basic Information | MarketWatch